Macrolides in the management of streptococcal pharyngitis/tonsillitis

Pediatric Infectious Disease Journal

Volumn 16, Issue 4, 1997, Pages 444-448

  Tarlow, Michael J ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Azithromycin; clarithromycin; erythromycin; penicillin; streptococcal pharyngitis; Streptococcus pyogenes; tonsillitis

Indexed keywords

AZITHROMYCIN; BENZATHINE PENICILLIN; CLARITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE; ERYTHROMYCIN ETHYLSUCCINATE; MACROLIDE; PENICILLIN G; PENICILLIN V; PENICILLIN V POTASSIUM;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PENICILLIN RESISTANCE; PHARYNGITIS; PRIORITY JOURNAL; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TONSILLITIS; VOMITING;

EID: 0030895338     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199704000-00028     Document Type: Conference Paper

References (24)

1. Pichichero ME. Therapeutic consideration for management of otitis media, sinusitis, and tonsillopharyngitis. Pediatr Asthma Allergy Immunol 1992;6:167-74.
2. Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician 1990;42:1567-76.
3. Bisno AL. Streptococcus pyogenes. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:1786-99.
4. Peter G. Streptococcal pharyngitis: current therapy and criteria for evaluation of new agents. Clin Infect Dis 1992; 14(Suppl 2):S218-23.
5. Kaplan EL. Benzathine penicillin G for treatment of group A streptococcal pharyngitis: a reappraisal in 1985. Pediatr Infect Dis J 1985;4:592-6.
6. Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991;10:275-81.
7. Vukmir RB. Adult and pediatric pharyngitis: a review. J Emerg Med 1992;10:607-16.
8. Congeni BL. The resurgence of acute rheumatic fever in the United States. Pediatr Ann 1992;21:816-20.
9. Baquero F, Loza E. Antibiotic resistance of microorganisms involved in ear, nose and throat infections. Pediatr Infect Dis J 1994;13:S9-14.
10. Jacoby GA. Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis 1994;18: 951-7.
11. Klein JO. Selection of oral antimicrobial agents for otitis media and pharyngitis. Infect Dis Clin Pract 1994;3:151-7.
12. Still JG, Hubbard WC, Poole JM, Sheaffer CI, Chartrand S, Jacobs R. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. Pediatr Infect Dis J 1993;12:S134-41.
13. Still JG. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995;14:S57-61.
14. Brook I. The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis 1984;6:601-7.
15. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-9.
16. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U. S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
17. Guay DRP. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J 1993;12:S106-11.
18. Fish DN, Gotfried MH, Danziger LH, Rodvold KA. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother 1994;38: 876-8.
19. Anderson R, Joone G, van Rensburg CEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988;22:923-33.
20. Craft JC, Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr Infect Dis J 1993;12:S142-7.
21. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
22. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
23. Still JG. Treatment of streptococcal pharyngitis in children with five days of azithromycin suspension [Abstract M67]. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994. Washington, DC: American Society for Microbiology, 1994.
24. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37(Suppl C):143-9.